Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermediate-dose HAD Regimen for CEBPA Double-mutated Acute Myeloid Leukemia
NCT06529250Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Event-free survival up to 2 years. Started Aug 2024; status: recruiting.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06529250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06529250.